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Abstract
Background: O-(2-18 F-fluoroethyl)-L-tyrosine-(FET)-PET may be helpful to improve the definition of radiation target
volumes in glioblastomas compared with MRI. We analyzed the relapse patterns in FET-PET after a FET- and
MRI-based integrated-boost intensity-modulated radiotherapy (IMRT) of glioblastomas to perform an optimized
target volume definition.
Methods: A relapse pattern analysis was performed in 13 glioblastoma patients treated with radiochemotherapy
within a prospective phase-II-study between 2008 and 2009. Radiotherapy was performed as an integrated-boost
intensity-modulated radiotherapy (IB-IMRT). The prescribed dose was 72 Gy for the boost target volume, based on
baseline FET-PET (FET-1) and 60 Gy for the MRI-based (MRI-1) standard target volume. The single doses were 2.4
and 2.0 Gy, respectively. Location and volume of recurrent tumors in FET-2 and MRI-2 were analyzed related to
initial tumor, detected in baseline FET-1. Variable target volumes were created theoretically based on FET-1 to
optimally cover recurrent tumor.
Results: The tumor volume overlap in FET and MRI was poor both at baseline (median 12 %; range 0–32) and at
time of recurrence (13 %; 0–100). Recurrent tumor volume in FET-2 was localized to 39 % (12–91) in the initial
tumor volume (FET-1). Over the time a shrinking (mean 12 (5–26) ml) and shifting (mean 6 (1–10 mm) of the
resection cavity was seen. A simulated target volume based on active tumor in FET-1 with an additional safety
margin of 7 mm around the FET-1 volume covered recurrent FET tumor volume (FET-2) significantly better than a
corresponding target volume based on contrast enhancement in MRI-1 with a same safety margin of 7 mm (100 %
(54–100) versus 85 % (0–100); p < 0.01). A simulated planning target volume (PTV), based on FET-1 and additional
7 mm margin plus 5 mm margin for setup-uncertainties was significantly smaller than the conventional, MR-based
PTV applied in this study (median 160 (112–297) ml versus 231 (117–386) ml, p < 0.001).
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Conclusions: In this small study recurrent tumor volume in FET-PET (FET-2) overlapped only to one third with the
boost target volume, based on FET-1. The shrinking and shifting of the resection cavity may have an influence
considering the limited overlap of initial and relapse tumor volume. A simulated target volume, based on FET-1
with 7 mm margin covered 100 % of relapse volume in median and led to a significantly reduced PTV, compared
to MRI-based PTVs. This approach may achieve similar therapeutic efficacy but lower side effects offering a broader
window to intensify concomitant systemic treatment focusing distant failures.
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Introduction
To date, external fractionated radiotherapy is a mainstay
in the multimodal treatment strategy of glioblastomas.
The diagnostic method of choice for radiation treatment
planning is contrast-enhanced MRI owing to its higher
anatomical contrast and spatial resolution compared
with CT. The differentiation of glioma tissue from sur-
rounding edema, however, may be difficult with MRI
and CT particularly when the tumor is not sharply de-
lineated from normal brain tissue, and when the blood-
brain barrier (BBB) remains intact [1]. Tumor cells have
been detected beyond the margins of contrast enhance-
ment, in the perifocal edema, and even in the adjacent
normal-appearing brain parenchyma [2, 3]. Furthermore,
after neurosurgical resection BBB disturbances and
edema can also be treatment-related and cannot be dif-
ferentiated from residual tumor or tumor recurrence/
progression using conventional MRI [4]. In order to
cover all brain areas potentially infiltrated by the tumor,
these difficulties lead to rather large target volumes for
radiotherapy of glioblastoma [5–9].
In the last decades, amino acid PET using O-(2-18F-
fluoroethyl)-L-tyrosine (FET) or L-[methyl-11C]methio-
nine (MET) have been shown to be particularly useful to
determine the extent of cerebral gliomas more precisely
than conventional MRI alone [10–15]. Incorporating
such molecular or “biological” imaging information has
generated the radiooncological concept of the so called
“biological target volume” (BTV) [16]. A number of cen-
ters have started to integrate amino acid imaging into
CT- and MRI-based radiotherapy planning, particularly
when high-precision radiotherapy is planned or in the
setting of dose escalation studies or for the re-irradiation
of recurrent tumors [17–21].
Some studies have examined the recurrence pattern of
glioblastoma in relation to the planning target volume
(PTV), either based on treatment planning including
FET-PET [22], on MET uptake in the baseline study
without using PET for planning [23] or based on the
localization of tumor recurrence using FET-PET [24].
The matching observation of all these studies was that
the recurrences occurred mainly within the PTV. These
studies raised the question whether the “in-field”-
recurrences can be reduced by dose escalation to the
FET-based BTV, e.g., as a stereotactic dose escalation or
by means of a simultaneous integrated boost.
In a recent prospective phase-II trial we performed an
integrated-boost intensity-modulated radiotherapy (IB-
IMRT) with a dose escalation concept giving 72 Gy in
30 fractions to the boost volume based on pre-
irradiation 18F-FET PET imaging [25]. Compared with
historical controls and published MRI-based dose-
escalation studies, however, no improvement of
progression-free or overall survival could be observed.
Despite this disappointing result, there remains the
notion to optimize the irradiation volume using FET
PET and thus to possibly reduce side effects. Therefore,
we reviewed the follow-up data of the patients in the
above-mentioned study in order to analyze the overlap be-
tween residual tumor in the baseline FET-PET (FET-1)
post-surgery and the relapse tumor volumes as detected
also by FET-PET (FET-2). Based on the results different
radiation target volumes were simulated in order to
achieve optimal coverage of the tumors with minimal ir-
radiation volume.
To the best of our knowledge, this is the first study
comparing the tumor volume in FET PET and MRI at
the time of radiation treatment planning to that of FET
PET and MRI at the time of tumor recurrence.
Material and methods
Ethical consideration
This study was approved by the university ethics com-
mittee at the RWTH Aachen faculty of medicine (Ref.
No. EK027/07). All participants had given written in-
formed consent for their participation in the study and
for publication of the data.
Patients
This retrospective analysis is based on a previous pro-
spective phase II study [25]. In that study, 22 patients
with primary glioblastoma (median age, 55 years; range,
36–73 years) were treated with radiotherapy and concomi-
tant temozolomide chemotherapy (RCX) followed by adju-
vant temozolomide between 01/2008 and 12/2009 [25]. All
patients had pre- and postoperative MRI (T1-, T2- and
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FLAIR-weighted images) and postoperative FET-PET for
radiation treatment planning. The respective MRI- and
FET-PET scans, initial (FET-PET1/MRI1) and also at time
of relapse (FET-PET2/MRI2), were performed on the same
day. Thereafter, all patients were treated with an IB-IMRT.
Within the follow-up time of 15 months (range, 3–
34 months) 19 patients presented with tumor recurrence
on contrast-enhanced MRI. According to the graduation
used by Chan et al. [26], a local, local and distant, and
distant only recurrence on MRI was seen in 15, 3, and 1
patient(s), respectively. In 13 patients, a repeated FET-
PET scan was done so that MRI and PET data were
available both at the time of the planning of radiother-
apy and at the time of recurrence. These 13 patients
were included in this relapse pattern analysis. Due to a
poor medical condition at the time of recurrence, in the
remaining 6 patients FET-PET could not be obtained.
18F-FET PET imaging
The amino acid 18F-FET was produced via nucleophilic
18F-fluorination with a specific radioactivity of >200 GBq/
μmol as described previously. Dynamic PET studies were
acquired up to 50 min after intravenous injection of
200 MBq FET in 3-dimensional mode and reconstructed
as described previously [27]. The subsequent evaluation
was based on the summarized FET-PET data from 20 to
40 min post injection.
Radiotherapy
The clinical target volumes (CTV) and planning target
volume (PTV) were defined as previously described [25].
In brief, a CTV1 was defined from the postoperative
FET-PET using an autocontouring process using a
tumor-to-brain ratio (TBR) of FET uptake ≥1.6, which is
equivalent to the BTV as mentioned above. This cut-off
is based on a biopsy-controlled study in cerebral gliomas
where a TBR of 1.6 separated best tumoral from peritu-
moral tissue [14]. Further, a CTV2 was defined as the
contrast-enhanced area from pre- and postoperative
MRI including a safety margin of 1.5 cm and including
the preoperative edema, individually adapted to organs
at risk and osseous structures. The PTV1 was based on
CTV1 with no additional margin. The PTV2 was gener-
ated automatically by adding a 0.5 cm margin around
the CTV2. The whole dose was 72 Gy for the PTV1 and
60 Gy for the PTV2 applied with an IB-IMRT (single
doses 2.4 and 2 Gy, respectively).
Analysis of tumor volumes at baseline and at the time of
recurrence
In order to analyze the spatial relationship of tumor vol-
umes derived from contrast enhancement in MRI and
FET PET at baseline for radiation treatment planning
and at the time of recurrence the corresponding data
sets were transferred to the Philips Syntegra™ image
registration tool. After coregistration of MRI and FET-
PET scans the different volumes were compared volu-
metrically. The contouring and volume analysis was
performed using the Philips Pinnacle3 treatment plan-
ning software (Version 8.0 m, Philips Medical Systems,
Eindhoven, NL).
The volume of the tumor showing contrast enhance-
ment of Gd-DTPA on T1-weighted MRI was determined
in baseline MRI for radiation treatment planning (MRI-1)
and at the time of relapse (MRI-2). Correspondingly, the
tumor volume of FET uptake with a TBR ≥ 1.6 was evalu-
ated in the baseline FET PET scan (FET-1) and at the time
of recurrence (FET-2).
Intersect tumor volumes of Gd-enhancement in MRI
and of increased FET-uptake at baseline (MRI-1 ∩ FET-1)
and corresponding intersect at the time of relapse
(MRI-2 ∩ FET-2) were determined.
Analysis of the location of tumor recurrence in relation to
PTV1 and PTV2
The primary aim of this study was to analyze the loca-
tion of the tumor recurrence in FET PET in relation to
the tumor area irradiated with a 72 Gy boost (PTV1)
which was based on initial FET PET. Furthermore, the
recurrence pattern in FET PET in relation to brain area
irradiated with a conventional dose of 60 Gy (PTV2)
was also considered. This analysis was based on the
evaluation of FET-PET data because increased tracer up-
take can be considered as a more reliable parameter to
determine metabolically active recurrent tumor than
contrast enhancement on MRI [28, 29]. For this purpose
the tumor volume and fraction of FET positive recurrent
tumor within the area irradiated with 60 Gy (PTV2) and
within the boost area irradiated with 72 Gy (PTV1) was
determined (Table 2).
Analysis of shifting and shrinking of the resection cavity
The shrinking of the resection cavity was analyzed,
measuring the volume of the cavity initial and at time of
relapse comparatively. Also, the shifting was analyzed
measuring the shift of a manually determined represen-
tative center point within the cavity.
Simulation of the optimal target volume to cover
potential relapse areas
Based on FET-PET and MRI at baseline (FET-1 and
MRT-1) different target volumes were simulated in order
to analyze the coverage of the recurrent tumors in FET-2.
Therefore, the surface of baseline tumor volumes in FET-
1 and of contrast enhancement in MRI-1 were surrounded
by expanded volumes at a distance of 5, 7 and 10 mm to
generate different target volumes.
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Statistical analysis
The Wilcoxon test was used to compare the tumor vol-
umes and coverage of recurrent tumor tissue by different
simulated PTVs based on FET-PET and contrast-
enhanced MRI. The global significance level for the stat-
istical test procedure conducted was chosen as α = 5 %.
Statistical analysis was performed using the SPSS Statis-
tics software (Release 20.0, SPSS Inc., Chicago, IL, USA)
software.
Results
Analysis of tumor volumes at baseline and at the time of
recurrence
The tumor volumes for each patient at baseline (FET-1
and MRI-1) and at the time of recurrence (FET-2 and
MRI-2) are shown in Table 1. At baseline, the median
tumor volume in FET-PET (FET-1) was significantly lar-
ger than that of contrast enhancement on MRI-1 (9
(range 1–63) ml vs. 5 (0.6–20) ml; p = 0.01) while there
was no significant difference between the tumor volumes
of FET-PET and MRI at the time of recurrence (FET-2
and MRI-2; 13 (4–67) ml vs. 19 (4–113) ml; p = 0.7) The
intersect between increased FET uptake (TBR > 1.6) and
contrast enhancement in MRI was generally poor both
at baseline and at the time of relapse (12 % (0–32) and
13 % (0–100), respectively). The discrepancy between
FET uptake and contrast enhancement on MRI is illus-
trated in Fig. 1b and d.
Analysis of the location of tumor recurrence in relation to
PTV1 and PTV2
Data on the location of pathological tracer uptake in
FET PET in relation to PTV1 and PTV2 at the time of
tumor recurrence are shown in Table 2. The fraction of
the recurrent FET tumor volume within the 72 Gy boost
volume PTV1, was only 39 % (12–91), i.e., nearly two
thirds of recurrent tumor tissue was located outside the
boost volume. In contrast, recurrent FET tumor volume
was located to 100 % within the large PTV-2 based on
conventional MRI which was irradiated by the standard
dose of 60 Gy.
Analysis of shifting and shrinking of the resection cavity
The resection cavity shrinked by 12 ml (4.8–26) and
shifted by 6 mm (1–10.3) in mean over time.
Simulation of the optimal PTV to cover potential
recurrence areas
The target volumes simulated on the basis of FET-PET
after resection (FET-1) exhibited generally better coverage
of the recurrent FET tumor volume (FET-2) than the cor-
responding target volumes simulated on the basis of the
Table 1 Tumor volumes of increased FET-uptake and of Gd-enhancement in MRI at baseline and at time of relapse
Pat. No Tumor volumes at baseline Tumor volumes at relapse
FET-1 (ml) MRI-1 (ml) Intersect FET-1 ∩
MRI-1 (ml)
Intersect FET-1 ∩
MRI-1 (% of FET-1)
FET-2 (ml) MRI-2 (ml) Intersect FET-2 ∩
MRI-2 (ml)
Intersect FET-2 ∩
MRI-2 (% of FET-2)
1 10.4 0.8 0.4 3.8 3.7 3.7 0.0 0
2 6.9 0.6 0.2 2.9 10.9 8.9 0.7 8.7
3 6.8 3.7 2.2 32.4 11.3 8.1 5.0 44.2
4 1.1 6.8 1.3 9.9 12.2 9.3 7.6 62.3
5 13.4 6.0 3.5 26.1 13.9 12.0 1.1 7.9
6 15.0 1.3 0.5 3.3 35.1 16.2 23.5 67.0
7 6.7 6.4 0.0 0.0 6.2 19.4 0.8 12.9
8 25.2 1.3 1.3 5.2 22.1 26.8 10.0 45.3
9 4.7 6.5 1.5 31.9 5.6 27.0 5.6 100
10 6.8 4.9 1.6 23.5 56.0 39.6 0.0 0.0
11 62.9 19.4 12.0 19.1 46.7 41.8 23.4 50.1
12 59.0 19.5 11.3 19.2 66.8 43.5 5.5 8.2
13 9.1 1.1 1.1 12.1 12.8 113.0 1.7 13.3
Mean 17.5 6.0 3.0 14.6 23.3 28.4 6.5 32.3
Median 9.1 4.9 1.3 12.1 12.8 19.4 5.0 13.3
SD 19.6 6.1 4.0 11.5 20.9 28.8 8.1 31.5
range 1.1–62.9 0.6–19.5 0–12 0–32.4 3.7–66.8 3.7–113 0–23.5 0-100.0
FET-1: pathological FET-Volume in ml at baseline (post surgery)
MRI-1: Gd-contrast-enhancement in ml at baseline (post surgery)
FET-2: pathological FET-Volume in ml at the time of relapse
MRI-1: Gd-contrast-enhancement in ml at the time of relapse
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Fig. 1 Residual tumor volumes in FET-PET and MRI after glioblastoma resection left frontal are shown in the upper row (a, b) and of the recurrent
tumor in the lower row (c, d). The tumor volume with increased FET uptake is surrounded by a dotted line in FET-PET (a, c) and by a green line
in contrast-enhanced MRI (b, d). Note the discrepancy between FET uptake and contrast enhancement both in the baseline scan (b) and at the
time of relapse (d). The definition of PTV2, which is based on MRI, is indicated by the red line (b, d). The blue line demonstrated a simulated PTV
based on a CTV consisting of FET-1 plus 7 mm margin
Table 2 FET-uptake at time of relapse in relation to PTV-1 and PTV-2
Pat. No FET Tumor volume at relapse PTV-1 (72 Gy) PTV-2 (60 Gy)
FET-2 (ml) Part of FET-2 in PTV-1 (ml) Fraction of FET-2 in PTV-1 (%) Fraction of FET-2 in PTV-2 (%)
1 3.7 1.2 11.5 100
2 10.9 1.1 15.9 100
3 11.3 3.8 55.9 100
4 12.2 5.1 38.9 100
5 13.9 4.9 36.6 100
6 35.1 13.7 91.3 100
7 6.2 1.6 23.9 100
8 22.1 9.5 37.7 100
9 5.6 0.6 12.8 100
10 56.0 2.8 41.2 100
11 46.7 29.4 46.7 100
12 66.8 29.0 49.2 100
13 12.8 4.4 48.4 100
Mean 23.3 8.2 39.2 100
Median 12.8 4.4 38.9 100
SD 20.9 10.0 21.4
Range 3.7–66.8 0.6–29.4 11.5–91.3
FET-2: pathological FET-Volume in ml at the time of relapse
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contrast-enhanced MRI (Table 3). Thus theoretically, a
CTV based on FET-1 without any margin showed a sig-
nificant better coverage of FET-2 than a corresponding
target volume based on contrast enhancement in MRI-1
(median 34 % (5–63) vs. 21 % (0–42); p < 0.01), FET-1 and
MRI-1 with a margin of 5 mm (94 % (42–100) vs. 74 %
(0–92); p < 0.01), FET-1 and MRI-1 with a margin of
7 mm (100 % (54–100) vs. 85 % (0–100); p < 0.01), FET-1
and MRI-1 with a margin of 10 mm (100 % (82–100) vs.
86 % (0–100); p < 0.01).
The resulting simulated PTVs on the basis of FET-
PET after surgery with different margins in comparison
with the actual PTV-2 from the study are shown in
Table 4.
An optimal compromise appears to be a CTV based
on FET-1 with a margin of 7 mm because there is a high
coverage of recurrent tumor volume in FET-PET (100 %
(54–100)) and a significantly smaller PTV compared to a
typical MRI-based PTV performed in our study (160
(112–297) ml vs. 231 (117–386) ml, p < 0.001).
Discussion
To date, the definition of the optimal target volume in
radiation treatment planning of glioblastomas is contro-
versial [30, 31]. According to current standards, target
volume concepts are based on either preoperative or
postoperative MRIs, which, however, lead to relative
large target volumes [5–9]. PET using radiolabeled
amino acids such as FET can offer a more precise delin-
eation of the metabolically active tumor, which is not
limited to the area of BBB disruption and is more spe-
cific than the information provided by conventional MRI
alone [14, 32, 33]. A number of centers have started to
integrate the BTV as depicted by amino acid PET into CT-
and MRI-based radiotherapy planning [12, 17–20, 24].
Considerable discrepancies between the PTVs arising from
MRI and PET have been demonstrated in several studies
[12, 17, 19, 24, 34].
In addition to the observed differences in the extent
of the tumor in MRI and PET in radiotherapy plan-
ning, the localization and the definition of the extent
of the recurrent tumor is another diagnostic problem.
Treatment-related BBB alterations with consecutive con-
trast enhancement on conventional MRI can mimic tumor
recurrence and are difficult to differentiate from progres-
sive tumor. It has been shown in several studies that FET
PET is more reliable to differentiate tumor tissue in recur-
rent gliomas and posttherapeutic changes in the tissue
than conventional MRI [11, 28, 35].
Some studies have examined the recurrence pattern of
glioblastoma taking into account amino acid PET in
various ways. One study included FET-PET for RT plan-
ning but the location of recurrences was evaluated by
contrast enhanced MRI only [22]. Another study analyzed
Table 3 Coverage of recurrent FET tumor volume by different simulated CTVs based on PET/MRI at baseline
CTV MRI-1 FET-1 MRI-1 FET-1 MRI-1 FET-1 MRI-1 FET-1
No margin +5 mm margin +7 mm margin +10 mm margin
1 0,27 0,33 0,8 0,95 0,87 1,00 0,93 1,00
2 0,08 0,098 0,49 0,61 0,52 0,76 0,7 1,00
3 0,21 0,34 0,61 0,95 0,67 1,00 0,83 1,00
4 0,33 0,42 0,74 0,94 0,85 1,00 0,86 1,00
5 0,25 0,35 0,92 0,96 0,99 1,00 1,00 1,00
6 0,05 0,39 0,19 0,85 0,23 0,92 0,33 0,972
7 0 0,25 0 0,831 0 0,91 0 0,98
8 0,2 0,32 0,76 0,93 1,00 1,00 1,00 1,00
9 0,08 0,11 0,79 0,84 0,88 0,91 0,9 0,95
10 0,16 0,05 0,55 0,42 0,62 0,54 0,84 0,82
11 0,42 0,63 0,51 0,96 0,578 0,97 0,77 1,00
12 0,3 0,44 0,79 1,00 0,90 1,00 0,96 1,00
13 0,22 0,34 0,91 1,00 1,00 1,00 1,00 1,00
mean 0,20 0,31 0,62 0,86 0,70 0,92 0,78 0,98
median 0,21 0,34 0,74 0,94 0,85 1 0,86 1
SD 0,12 0,16 0,27 0,17 0,31 0,13 0,39 0,05
range 0-0,42 0,05-0,63 0-0,92 0,42-1 0-1 0,54-1 0-1 0,82-1
CTV Clinical Target Volume
FET-1 pathological FET-Volume in ml at baseline (post surgery)
MRI-1: Gd-contrast-enhancement in ml at baseline (post surgery)
SD Standard Deviation
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the location of recurrences in contrast-enhanced MRI in
comparison to MET uptake in the baseline study without
using PET for treatment planning [23]. A recent study in-
vestigated the localization of tumor recurrence in FET-
PET after re-irradiation with bevacizumab in recurrent
malignant gliomas [24]. The matching observation of all
these studies was that the recurrences occurred mainly
within the PTV but it has to be considered that in no
study amino acid PET was available in both the baseline
study and at the time of relapse.
In this retrospective study we analyzed relapse patterns
of glioblastoma in FET-PET and MRI after IB-IMRT
with dose escalation based on FET-PET.
A first aspect in this study was the comparison of the
extent of contrast enhancement on MRI to that of FET
uptake in the baseline study and at the time of recurrence.
In agreement with previous studies the intersection be-
tween pathological FET uptake and contrast enhancement
in MRI was generally poor both at baseline and at the time
of recurrence. This observation confirms the view that
contrast enhancement in MRI does not reliably reflect the
extent of the metabolically active tumor volume and
should be therefore considered with caution [12, 17, 19,
24, 34]. Tumor volumes in FET-PET and contrast-
enhanced MRI were not significantly different at the time
of relapse and the overlap was 13 % in median only.
The comparison of the relapse volume in FET-PET in
relation to PTV2 demonstrated that 100 % of the tumor
recurrences were located in the routinely performed
large target volumes using MRI based treatment plan-
ning [5–9]. This is in agreement with the results of pre-
vious studies including PET data [22–24] and is also in
accordance with the literature based on conventional
imaging where all local relapses were detected within
the volume enclosed by the 95 % isodosis line of the pre-
scribed dose of 60 Gy [26, 36, 37]. This is not unex-
pected, since radiation treatment planning based on MRI
scans usually encompass the resection cavity and the
contrast enhancing area with a margin up to 3 cm [5],
resulting in large radiation target volumes.
Comparison of the relapse volume in FET-PET in rela-
tion to the boost target volume applied in our study,
however, revealed that more than two thirds of recurrent
tumor tissue in FET-PET was located outside the boost
volume. The limited overlap may be influenced by the
shifts of brain tissue due to shrinkage of the resection
cavity seen in our analysis (see Fig. 1) but the difference
is considerable and cannot be explained solely by these
factors. Therefore it can be assumed that a large propor-
tion of recurrences have grown outside the boost vol-
umes i.e. within the area of the prescribed dose of
60 Gy.
Table 4 Volumes of standard and simulated PTVs on the basis of FET-PET
Pat. No. PTV-2 MRI
standard (ml)
PTV FET-1
+5 mm margin (ml)
PTV FET-1
+7 mm margin (ml)
PTV FET-1
+10 mm margin (ml)
1 245 122 147 214
2 164 98 118 163
3 117 92 112 143
4 248 125 150 194
5 161 101 114 146
6 256 182 213 286
7 224 106 126 166
8 348 216 253 308
9 209 161 187 259
10 160 138 160 216
11 364 233 263 304
12 386 265 297 342
13 231 175 197 258
mean 240 155 180 230
median 231 138 160 216
SD 83 56 62 67
Range 117–386 92–265 112–297 143–342
(Volumes of conventional PTV2 and simulated PTVs based on FET uptake at baseline (FET-1) expanded by 5, 7 and 10 mm margin in ml. The PTV include an
additional margin of 5 mm around the CTV which is standardly used to compensate the set-up- and immobilisation uncertainties)
PTV Planning Target Volume
FET-1: pathological FET-Volume in ml at baseline (post surgery)
MRI-1:Gd-contrast-enhancement in ml at baseline (post surgery)
SD Standard Deviation
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Based on this assumption we simulated different CTVs
on the basis of FET-PET in order to analyze the cover-
age of the recurrent tumors in FET-PET. The CTVs sim-
ulated on the basis of FET-PET after surgery exhibited
generally better coverage of the recurrent FET tumor
volume than the corresponding CTVs simulated on the
basis of the contrast-enhanced MRI. Using a CTV based
on FET-1 with a margin of 7 mm achieved a high cover-
age of recurrent tumor volume in FET-PET of 100 %
(54–100). Accordingly, a significantly smaller PTV re-
sults compared to the conventional MR-based PTV used
in this study (160 (112–297) ml vs. 231 (117–386) ml,
p < 0.001). This analysis indicates that a PTV based on
FET-PET may achieve a coverage which is at least com-
parable to standard MRI-based PTVs but less toxic
considering the shown PTV reduction. This approach
may help to achieve similar therapeutic efficacy but
lower side effects. This may be of interest with regard
to an intensification of concomitant systemic treatment
schemes probably required to improve outcome. Fur-
thermore, sparing of larger parts of the brain increases
the systemic treatment options in the case of distant
recurrences.
Conclusion
Overlap of pathological FET uptake in glioblastoma and
contrast enhancement in MRI was generally poor both
at baseline and at the time of relapse. Relapse volumes
of the tumor recurrences in FET-PET were located to
100 % in PTV2 achieving 60 Gy, but more nearly two
thirds was located outside the boost volume PTV1. A
CTV based on FET with a safety margin of 7 mm covers
100 % of the relapse volume and consecutively reduces
the PTV significantly. This approach may achieve similar
therapeutic efficacy but lower side effects and offer op-
tions to intensify concomitant systemic treatment focus-
ing the problem of distant failures. Because of the small
sample size further studies are needed to confirm these
findings.
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